4.7 Article

Gut Dysbiosis and Detection of Live Gut Bacteria in Blood of Japanese Patients With Type 2 Diabetes

Journal

DIABETES CARE
Volume 37, Issue 8, Pages 2343-2350

Publisher

AMER DIABETES ASSOC
DOI: 10.2337/dc13-2817

Keywords

-

Funding

  1. Kissei Pharma
  2. Sanofi
  3. Takeda Pharmaceutical Co.
  4. MSD
  5. Boehringer Ingelheim
  6. Eli Lilly
  7. Novartis Pharmaceuticals
  8. Dainippon Sumitomo
  9. Novo Nordisk Pharma
  10. Daiichi Sankyo
  11. Kowa
  12. Mochida
  13. Sanwakagaku
  14. Novartis
  15. Tanabe Mitsubishi
  16. Telmo
  17. Sanofi Aventis
  18. Roche
  19. Ono
  20. Yakult Honsha Co. Ltd.
  21. Ono Pharmaceutical Co.
  22. Sanwakagaku Kenkyusho
  23. Daiichi Sankyo Inc.
  24. Dainippon Sumitomo Pharmaceuticals
  25. Kowa Co.
  26. Pfizer
  27. Mochida Pharmaceutical Co.
  28. Terumo Corporation
  29. Mitsubishi Tanabe Pharma
  30. Shionogi Pharma
  31. Dainippon Sumitomo Pharma
  32. AstraZeneca

Ask authors/readers for more resources

OBJECTIVE Mounting evidence indicates that the gut microbiota are an important modifier of obesity and diabetes. However, so far there is no information on gut microbiota and live gut bacteria in the systemic circulation of Japanese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Using a sensitive reverse transcription-quantitative PCR (RT-qPCR) method, we determined the composition of fecal gut microbiota in 50 Japanese patients with type 2 diabetes and 50 control subjects, and its association with various clinical parameters, including inflammatory markers. We also analyzed the presence of gut bacteria in blood samples. RESULTS The counts of the Clostridium coccoides group, Atopobium cluster, and Prevotella (obligate anaerobes) were significantly lower (P < 0.05), while the counts of total Lactobacillus (facultative anaerobes) were significantly higher (P < 0.05) in fecal samples of diabetic patients than in those of control subjects. Especially, the counts of Lactobacillus reuteri and Lactobacillus plantarum subgroups were significantly higher (P < 0.05). Gut bacteria were detected in blood at a significantly higher rate in diabetic patients than in control subjects (28% vs. 4%, P < 0.01), and most of these bacteria were Gram-positive. CONCLUSIONS This is the first report of gut dysbiosis in Japanese patients with type 2 diabetes as assessed by RT-qPCR. The high rate of gut bacteria in the circulation suggests translocation of bacteria from the gut to the bloodstream.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available